Quality investing is built on the idea of owning companies with durable competitive advantages, consistent profitability, and strong financial discipline—businesses you’d be comfortable holding for years. One practical way to identify such names is through a structured stock screener, and the Caviar Cruise screen is designed specifically for this purpose. Inspired by the principles of quality investing, this screen filters for companies that demonstrate not just growth, but profitable growth, sound balance sheets, and high returns on capital. LeMaitre Vascular Inc. (NASDAQ:LMAT) is one of the names that emerges from this process, and a closer look at its numbers shows why it fits the mold.
Why LeMaitre Vascular Passes the Quality Test
The Caviar Cruise screen looks for companies that have grown revenue and EBIT by at least 5% annually over the past five years, with EBIT growth outpacing revenue growth—a sign of improving operational efficiency. LeMaitre Vascular checks these boxes handily. Its revenue compound annual growth rate (CAGR) over the past five years stands at 9.67%, while its EBIT CAGR is even stronger at 19.13%. This gap between the two indicates that the company is not just selling more; it’s becoming more profitable on each sale, a hallmark of pricing power and economies of scale.
The screen also emphasizes a high return on invested capital (ROIC), specifically the variant excluding cash, goodwill, and intangibles. LeMaitre’s ROIC on this basis is an impressive 42.9%, far above the 15% threshold the screen requires. A high ROIC like this suggests the company is deploying its capital efficiently, generating substantial profits relative to the money invested in its core operations. For a quality investor, this is one of the most telling metrics—it signals that the business has a sustainable advantage that competitors find hard to replicate.
Financial Health and Profit Quality
Beyond growth and returns, the Caviar Cruise screen stresses financial resilience. It requires a debt-to-free-cash-flow ratio of less than five, meaning the company could theoretically pay off its debts quickly using its cash generation. LeMaitre’s ratio comes in at just 2.13, indicating a very manageable debt load. Its current ratio of 14.32 and quick ratio of 12.20 further underline a fortress-like balance sheet, with ample liquidity to cover short-term obligations.
Profit quality is another key filter, measured as the ratio of free cash flow to net income over five years, with a minimum of 75%. LeMaitre scores 106.2% here, meaning it actually converts more net income into free cash flow than the accounting profit suggests. This is a strong indicator that earnings are backed by real cash, not accounting adjustments. Combined with operating and profit margins that rank among the best in its industry (28.5% and 24.4%, respectively), the picture is one of a highly efficient, well-managed business.
A High-Level Look at the Fundamentals
According to the fundamental analysis report, LeMaitre Vascular earns a rating of 7 out of 10. The standout areas are profitability, which scores a 9, and financial health, which scores an 8. These reflect strong returns on equity and assets, excellent margins, and a low bankruptcy risk as measured by an Altman-Z score of 7.73. The dividend profile is also notable—though the yield is modest at 1.06%, the company has grown its dividend at an annual rate of 16.13% over the past decade without interruption. On valuation, the report assigns a score of 4, a reminder that quality often comes at a price, but the growth outlook helps justify it.
Growth Trajectory and Future Outlook
The Caviar Cruise screen doesn’t ignore the future. The strict version of the screen requires expected revenue growth of at least 5% over the next three years, and analysts project LeMaitre will deliver nearly 10% annual revenue growth going forward. Earnings per share are expected to grow by about 12.3% annually. While the pace of growth may moderate compared to the past, the company still offers a solid forward trajectory, supported by its established product lines in vascular surgery and dialysis access.
Analyst Views
Market analysts have taken note of LeMaitre’s consistent execution. The stock currently trades at a price-to-earnings ratio of 35.6, which is above the S&P 500 average but below much of its industry peer group. The PEG ratio—which adjusts the P/E for earnings growth—suggests the valuation is reasonable given the expected growth rate. With strong profitability metrics to back it up, the premium is more justifiable than for many other names in the health care equipment space.
Find More Quality Candidates
LeMaitre Vascular is just one example of the type of company that surfaces when applying a disciplined quality screen. The Caviar Cruise approach helps investors cut through the noise and focus on businesses with proven fundamentals. To explore the full list of stocks that meet these stringent criteria, you can run the screen yourself and see which other names make the cut: [click here to access the Caviar Cruise screen](https://www.chartmill.com/stock/stock-screener?sid=673&f=sl_rev5y_5_X,sl_roicNg_15_X,sl_debt2fcf_X_5,sl_profitQ5y_75_X,sl_ebit5yGrowth_5_X,exch_us&v=22&s=ta&sd=DESC&cpl=2&bc=false&nw=1&o1=3&op1=200,16711680&o2=3&op2=50,255&o3=1&cf=(ebit5yGrowth%3Erev5y)>.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
LeMaitre Vascular Inc. (NASDAQ:LMAT) Passes the Quality Test with Caviar Cruise Screen
Quality investing is built on the idea of owning companies with durable competitive advantages, consistent profitability, and strong financial discipline—businesses you’d be comfortable holding for years. One practical way to identify such names is through a structured stock screener, and the Caviar Cruise screen is designed specifically for this purpose. Inspired by the principles of quality investing, this screen filters for companies that demonstrate not just growth, but profitable growth, sound balance sheets, and high returns on capital. LeMaitre Vascular Inc. (NASDAQ:LMAT) is one of the names that emerges from this process, and a closer look at its numbers shows why it fits the mold.
Why LeMaitre Vascular Passes the Quality Test
The Caviar Cruise screen looks for companies that have grown revenue and EBIT by at least 5% annually over the past five years, with EBIT growth outpacing revenue growth—a sign of improving operational efficiency. LeMaitre Vascular checks these boxes handily. Its revenue compound annual growth rate (CAGR) over the past five years stands at 9.67%, while its EBIT CAGR is even stronger at 19.13%. This gap between the two indicates that the company is not just selling more; it’s becoming more profitable on each sale, a hallmark of pricing power and economies of scale.
The screen also emphasizes a high return on invested capital (ROIC), specifically the variant excluding cash, goodwill, and intangibles. LeMaitre’s ROIC on this basis is an impressive 42.9%, far above the 15% threshold the screen requires. A high ROIC like this suggests the company is deploying its capital efficiently, generating substantial profits relative to the money invested in its core operations. For a quality investor, this is one of the most telling metrics—it signals that the business has a sustainable advantage that competitors find hard to replicate.
Financial Health and Profit Quality
Beyond growth and returns, the Caviar Cruise screen stresses financial resilience. It requires a debt-to-free-cash-flow ratio of less than five, meaning the company could theoretically pay off its debts quickly using its cash generation. LeMaitre’s ratio comes in at just 2.13, indicating a very manageable debt load. Its current ratio of 14.32 and quick ratio of 12.20 further underline a fortress-like balance sheet, with ample liquidity to cover short-term obligations.
Profit quality is another key filter, measured as the ratio of free cash flow to net income over five years, with a minimum of 75%. LeMaitre scores 106.2% here, meaning it actually converts more net income into free cash flow than the accounting profit suggests. This is a strong indicator that earnings are backed by real cash, not accounting adjustments. Combined with operating and profit margins that rank among the best in its industry (28.5% and 24.4%, respectively), the picture is one of a highly efficient, well-managed business.
A High-Level Look at the Fundamentals
According to the fundamental analysis report, LeMaitre Vascular earns a rating of 7 out of 10. The standout areas are profitability, which scores a 9, and financial health, which scores an 8. These reflect strong returns on equity and assets, excellent margins, and a low bankruptcy risk as measured by an Altman-Z score of 7.73. The dividend profile is also notable—though the yield is modest at 1.06%, the company has grown its dividend at an annual rate of 16.13% over the past decade without interruption. On valuation, the report assigns a score of 4, a reminder that quality often comes at a price, but the growth outlook helps justify it.
Growth Trajectory and Future Outlook
The Caviar Cruise screen doesn’t ignore the future. The strict version of the screen requires expected revenue growth of at least 5% over the next three years, and analysts project LeMaitre will deliver nearly 10% annual revenue growth going forward. Earnings per share are expected to grow by about 12.3% annually. While the pace of growth may moderate compared to the past, the company still offers a solid forward trajectory, supported by its established product lines in vascular surgery and dialysis access.
Analyst Views
Market analysts have taken note of LeMaitre’s consistent execution. The stock currently trades at a price-to-earnings ratio of 35.6, which is above the S&P 500 average but below much of its industry peer group. The PEG ratio—which adjusts the P/E for earnings growth—suggests the valuation is reasonable given the expected growth rate. With strong profitability metrics to back it up, the premium is more justifiable than for many other names in the health care equipment space.
Find More Quality Candidates
LeMaitre Vascular is just one example of the type of company that surfaces when applying a disciplined quality screen. The Caviar Cruise approach helps investors cut through the noise and focus on businesses with proven fundamentals. To explore the full list of stocks that meet these stringent criteria, you can run the screen yourself and see which other names make the cut: [click here to access the Caviar Cruise screen](https://www.chartmill.com/stock/stock-screener?sid=673&f=sl_rev5y_5_X,sl_roicNg_15_X,sl_debt2fcf_X_5,sl_profitQ5y_75_X,sl_ebit5yGrowth_5_X,exch_us&v=22&s=ta&sd=DESC&cpl=2&bc=false&nw=1&o1=3&op1=200,16711680&o2=3&op2=50,255&o3=1&cf=(ebit5yGrowth%3Erev5y)>.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Read full article here »